insights_auto
Prečo akcie 688235 stúpli 4,06%?
Preskúmať podrobnejšiechevron_right
688235:SHA
BeOne Medicines AG
255,98 CNY
arrow_upward
+4,06%(+9,99) 1 d.
16. 10., 15:00:00 GMT+8 · CNY
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre 688235…
Otvoriť
253,20 CNY
Vysoká
268,18 CNY
Nízka
252,09 CNY
Trh. kap.
303,26 mld.
Priem. obj.
2,81 mil.
Objem
5,69 mil.
Pomer cena/zárobky
91,43
Max. za 52 týž.
319,24 CNY
Min. za 52 týž.
205,51 CNY
Výnosy na akciu
2,80 CNY
Počet zamestnancov
12 tis.
Otvoriť
253,20 CNY
Vysoká
268,18 CNY
Nízka
252,09 CNY
Trh. kap.
303,26 mld.
Priem. obj.
2,81 mil.
Objem
5,69 mil.
Pomer cena/zárobky
91,43
Max. za 52 týž.
319,24 CNY
Min. za 52 týž.
205,51 CNY
Výnosy na akciu
2,80 CNY
Počet zamestnancov
12 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
ad-hoc-news.de
·
pred 1 dňom
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
MarketBeat
·
pred 3 dňami
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Informácie o subjekte BeOne Medicines AG
Generálny riaditeľJohn Vincent Oyler | John Vincent Oyler
Zamestnanci12 tis.
Dátum založenia28. 10. 2010
Hlavné sídlo-
Odvetvie-